ocrevus 30 mg/ml concentrate for solution for infusion
f.hoffmann-la roche ltd., switzerland - ocrelizumab - concentrate for solution for infusion - 300 mg
hemlibra 150 mg/ml solution for injection
roche, switzerland - emicizumab - solution for injection - 150 mg/ml
hemlibra 150 mg/ml solution for injection
roche, switzerland - emicizumab - solution for injection - 150 mg/ml
hemlibra 150 mg/ml solution for injection
roche, switzerland - emicizumab - solution for injection - 150 mg/ml
hemlibra 30 mg/ml solution for injection
roche, switzerland - emicizumab - solution for injection - 30 mg/ml
adynovate powder and solvent for solution for injection
baxalta us inc, united states - antihemophilic factor, pegylated (mw 20000) human sequence recombinant - powder and solvent for solution for injection - 500 iu
adynovate powder and solvent for solution for injection
baxalta us inc, united states - antihemophilic factor, pegylated (mw 20000) human sequence recombinant - powder and solvent for solution for injection - 250 iu
advate 500 iu powder and solvent for solution for injection
takeda manufacturing austria ag, austria - human coagulation factor viii - powder and solvent for solution for injection - 500 iu,
advate 250 iu powder and solvent for solution for injection
takeda manufacturing austria ag, austria - human coagulation factor viii - powder and solvent for solution for injection - 250 iu,
hyqvia 100mg/ml solution for infusion
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for infusion - 10 %